BCMA-iNKT-CAR for the Treatment of Multiple Myeloma

Basic Information

Funding Cycle : 2021-2022
Name : Julie O'Neal
Type of Award : Translational Research Award
Home Institution :  Washington University in St. Louis
Host Institution : N/A


The goal of this project was to test and characterize a BCMA targeted chimeric antigen receptor (CAR) that we expressed on invariant natural killer T cells (iNKT) for the treatment of multiple myeloma. The advantage of iNKT cells is that they do not cause GvDH, so are a potential “off the shelf” product which means they can be used as an allogeneic product. The advantages of allogeneic products are better cell fitness, reduced time to treatment, lower cost. We showed anti-myeloma efficacy of BCMA CAR-iNKT in vitro and in vivo. In vivo, the efficacy was not as good as BCMA CAR-T so we tested our hypothesis that BCMA CAR-iNKT efficacy would be improved with a long acting IL-7 (NT-I7) and found that BCMA CAR-iNKT plus NT-I7 significantly improved expansion/persistence of BCMA CAR-iNKT and in vivo efficacy. We tested the potential for BCMA CAR-iNKT to induce cytokine release syndrome (CRS) by comparing them to BCMA CART (positive control) and BCMA CAR NK-ML (negative control) and found BCMA CAR-iNKT may have an intermediate/lower propensity to induce CRS in this in vitro model.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Stay updated on our Events